JEITO

2024 has been a year of milestones for JEITO and its partners, as evidenced by three prestigious prizes won last week at the European Lifestars Awards Ceremony 🏆   🥇 𝗠&𝗔 𝗼𝗳 𝘁𝗵𝗲 𝗬𝗲𝗮𝗿: EyeBio & MSD. Six months ago, we announced the acquisition of our portfolio company EyeBio by MSD for a potential value of $3 billion.   🥈 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗖𝗘𝗢 𝗼𝗳 𝘁𝗵𝗲 𝗬𝗲𝗮𝗿: David Guyer, CEO of EyeBio, earned the second place, following this operation and the company’s significant clinical progress.   🥇 𝗟𝗮𝘁𝗲 𝗦𝘁𝗮𝗴𝗲 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗥𝗼𝘂𝗻𝗱 / 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖+: CatalYm GmbH, developing innovative immunotherapies to transform the lives of cancer patients, secured this award for its recent funding round, in which Jeito participated.   Congratulations to all! 👏   #lifestarsawards #privatequity #innovation #lifescience #biopharma

We are pleased to share that Rafaèle Tordjman, our Founder and CEO, has been honored with the prestigious "AM Leader" Prize 2024 at the "Grands Prix de L'AGEFI" ceremony last week.   This award recognizes outstanding leadership in the asset management industry, celebrating exceptional achievements and contributions to advancing the field.   It is also a testament to JEITO team's collective expertise and unwavering commitment to innovation to accelerate access to treatments for patients.   Congratulations to Rafaèle, and congratulations to the entire team! 👏 #AMLeader #privateequity #assetmanagement #innovation #biopharma

It was energizing to take part in the #JefferiesHealthcare conference and witness the continued momentum driving the biopharmaceutical sector forward.   The Jeito team had the opportunity to engage in insightful discussions with key players in the ecosystem.   Thank you, Jefferies, for hosting such a top-tier event dedicated to advancing healthcare innovation.   #privateequity #innovation #healthcare

Important step forward in the fight against Charcot-Marie-Tooth disease: our portfolio company NMD Pharma A/S dosed the first patient in its Phase 2a clinical trial of NMD670 👏   Following FDA IND clearance in June 2024, this progress brings hope to people affected by this highly debilitating disease for which no therapeutic options currently exist. "This is the only clinical study with a clinically feasible treatment to address the muscle weakness and fatigue with a pharmaceutical therapy at the moment," noted Yessar Hussain, MD, Austin Neurological Center, who led this initial stage.   Congratulations to the entire team!   Learn more about the trial 👉 https://lnkd.in/dkybnuwJ #FasterForThePatient #ALS #neuromusculardisease #biopharma #clinicaltrial #innovation

The next-generation targeted therapies developed by Alentis Therapeutics hold strong promise for treating Claudin-1 positive tumors. Today, we are thrilled to strengthen our support as part of Alentis' oversubscribed €164.5 million Series D funding round to accelerate their clinical progress! Since JEITO’s initial investment and co-lead roles in Alentis Therapeutics' Series B (2021) and Series C (2023) rounds, Alentis has progressed from pre-clinical research to multiple therapeutic programs in the clinic. Our renewed commitment reflects our strategy of supporting promising portfolio companies at each key value-creation milestones achieved by providing both substantial capital and expert guidance to unleash their potential. The entry of new leading international healthcare investors alongside the existing one is another evidence of Alentis exceptional innovation potential. Congratulations to Roberto Iacone and his team on this new milestone. Our team looks forward to continuing to support you! Read more about this announcement: https://lnkd.in/eazjHzF8 #privateequity #finance #innovation #lifesciences #biopharma #oncology

Our portfolio company Noema Pharma is advancing as part of its clinical progresses in Tourette Syndrome. 🔬   The first patient has now been dosed in a global Phase 2b study to assess the safety and efficacy of gemlapodect, an investigational therapy. The trial will enroll 140 patients with Tourette Syndrome across multiple centers in the US and Europe.   Congratulations to Noema Pharma team on this milestone, marking one more step toward a promising solution for thousands of patients.   Learn more 👉  https://lnkd.in/enz_fVNs   #TouretteSyndrome #innovation #biopharma #lifescience #clinicaltrial

Five months after the exit of our portfolio company Hi-Bio to Biogen, we are excited to share that the company has hit another value-creation milestone. Felzartamab, Biogen's investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for the treatment of severe immune-mediated diseases. The FDA grants BTD to drug candidates that address serious or life-threatening conditions and have preliminary clinical evidence demonstrating the potential to provide substantial improvements over existing therapies. This marks another step in bringing this promising drug candidate to patients, once again highlighting Jeito's ability to source high-quality biopharma. Read more 👉 https://lnkd.in/gUNjijjn #FasterForThePatient #innovation #biopharma #immunology

Congratulations to our portfolio company Noema Pharma for reaching a key clinical milestone in the treatment of Tourette Syndrome. 👏   In its Phase 2a clinical study, NOE-105 (gemlapodect) showed significant improvements for all patients, confirming its potential to offer a meaningful advancement in the treatment of Tourette syndrome. Today, over half a million individuals are suffering from Tourette Syndrome in the US alone, and millions worldwide.   Learn more about Noema's findings 👉 https://lnkd.in/gBatv5-H   #TouretteSyndrome #innovation #biopharma #clinicaltrial 

With robust growth and substantial value creation potential for patients, the biopharmaceutical sector stands out as one of the most promising to watch.   At #VCF24 organized by Invest Europe, Ksenija Pavletic, Partner at JEITO, outlined the market dynamics fueling this momentum:   ➡ The urgent need for new treatments, as two-thirds of known diseases still lack therapeutic options ➡ Big pharma Groups are approaching a patent cliff by 2030 and need to renew its innovation pipeline. At the same time, they are increasingly outsourcing R&D   In this environment, JEITO has developed a proven methodology, as demonstrated by our recent exits from EyeBio and HI-Bio: A Biogen Company, to accelerate the delivery of therapeutic innovations to patients. As Ksenija Pavletic emphasized, our approach is notably built on:   ➡ A rigorous selection process for scientific projects ➡ A multidisciplinary team that mirrors the highest standards of the pharmaceutical industry, ensuring the companies we support successfully navigate critical milestones, from clinical development to market access. ➡ A strategic refinancing approach that is essential for biopharma companies needing re-investment in continuity   We are grateful to Invest Europe for facilitating these valuable discussions!   #privateequity #lifesciences #biopharma #innovation #healthcare

We are thrilled to announce that JEITO has been selected to join the ILPA Summit, one of the most important private equity events worldwide.   Institutional Limited Partners Association (ILPA), the organization behind this prestigious event, is dedicated exclusively to the global Limited Partner community in private market.   Representing over 575 institutions and more than $2 trillion USD of private markets assets under management, ILPA’s members include public pensions, corporate pensions, endowments, foundations, family offices, insurance companies, and sovereign wealth funds located around the world.   Our participation highlights the relevance of our unique and differentiated investment strategy and our commitment to delivering value for patients and all our stakeholders. Attending ILPA? Our team will be there and happy to connect with you!   #ILPASummit24 #privateequity #investment #lifescience #biopharma